Antegren: Shaking Up the MS Market?

The dynamics of specialty chronic care markets suggest that Biogen Idec and Elan's highly anticipated Antegren may have trouble turning the scrappy $3.5 billion MS market on its head, at least right away.

By Christopher Morrison

When a drug from a new therapeutic class lands on the market, particularly in primary care categories, there are often...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from In Vivo Archive

More from In Vivo